Ollin Biosciences nets $330M Series B to run Phase 3 trials of Vabysmo challenger
What's the deal? Ollin Biosciences has raised a $330 million Series B to fund pivotal trials of its eye disease drug.
The company aims to develop a more potent rival to Genentech's Vabysmo, a blockbuster treatment for retinal conditions. Its candidate originates from China.
Why now? The fresh capital takes the drug into Phase 3, the costly, late-stage testing that decides whether a therapy reaches the market.
Vabysmo is one of the eye-care market's biggest sellers, leaving room for challengers that promise stronger or longer-lasting results.
What could go wrong? Late-stage trials are where many drugs fail, and a setback could erase the bet.
The China connection adds another layer of uncertainty, as US scrutiny of Chinese-origin biotech assets keeps rising.
The signal: Ollin's $330 million Series B lands among a string of recent ophthalmology and antibody raises — including Osanni Bio's $190 million eye-and-heart pipeline round — underscoring investor appetite for late-stage challengers to blockbuster eye drugs. As a clinical-stage company now pushing into pivotal trials, Ollin is testing whether a China-licensed asset can convert deep-pocketed backing into a credible threat to Vabysmo.
Read more: endpoints.news
Image credit: NavyMedicine
